The Potential of Osteopontin as a Therapeutic Target for Human Colorectal Cancer

Journal of Gastrointestinal Surgery

Volumn 15, Issue 4, 2011, Pages 652-659

  Likui, Wang ^a   Hong, Wang ^a   Shuwen, Zhang ^a   Yuangang, You ^a   Yan, Wen ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Invasion; Osteopontin; Radiosensitivity; RNA interference

Indexed keywords

MESSENGER RNA; OSTEOPONTIN;

ANIMAL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL TUMOR; DOWN REGULATION; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIATION DOSE; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; HUMANS; MICE; MICE, NUDE; OSTEOPONTIN; RADIATION TOLERANCE; RNA INTERFERENCE; RNA, MESSENGER; TUMOR STEM CELL ASSAY;

EID: 79953096751     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1445-6     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Asmis TR, Saltz L. Systemic therapy for colon cancer. Gastroenterol Clin North Am 2008; 37: 287-295.
3. Bulfone-Paus S, Paus R. Osteopontin as a new player in mast cell biology. Eur J Immunol 2008; 38: 338-341.
4. Hu Z, Xiao T, Lin DM, Guo SP, Zhang ZQ, Di XB, Cheng SJ, Gao YN. Zhonghua Zhong Liu Za Zhi 2007; 29: 591-595.
5. Patani N, Jouhra F, Jiang W, Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008; 28: 4105-4110.
6. Wu IC, Wu MT, Chou SH, Yang SF, Goan YG, Lee JM, Chou YP, Bair MJ, Wang TE, Chen A, Chang WH, Kuo FC, Wu DC. Osteopontin expression in squamous cell cancer of the esophagus. World J Surg 2008; 32: 1989-1995.
7. Cho H, Kang ES, Kim YT, Kim JH. Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest 2009; 27: 313-323.
8. Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 2007; 14: 3419-3427.
9. Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, Molinaro L, Scagliotti GV, Papotti M. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol 2008; 130: 58-64.
10. Likui W, Hong W, Shuwen Z. Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg 2010; 14: 74-81.
11. Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, Qin GJ, Liang G, Li JN, Han XF, Liu DX. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol 2009; 46: 2876-2884.
12. Zhang S, Yang JH, Guo CK, Cai PC. Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 2007; 253: 108-114.
13. Wu X, Fan J, Wang X, Zhou J, Qiu S, Yu Y, Liu Y, Tang Z. Downregulation of CCR1 inhibits human hepatocellular carcinoma cell invasion. Biochem Biophys Res Commun 2007; 355: 866-871.
14. Li W, Jian W, Xiaoping X, Yingfeng L, Tao X, Xiaoyan X. Enhanced radiation-mediated cell killing of human cervical cancer cells by small interference RNA silencing of ataxia telangiectasia-mutated protein. Int J Gynecol Cancer 2006; 16: 1620-1630.
15. Liu H, Chen A, Guo F, Yuan L A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 2010; 295: 27-37.
16. Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 2003; 90: 1556-1564.
17. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004; 90: 1877-1881.
18. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mänsson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1087-1097.
19. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94: 513-521.
20. Yeatman TJ, Chambers AF. Osteopontin and colon cancer progression. Clin Exp Metastasis 2003; 20: 85-90.
21. Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, Karl J. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res (2010); 16(24): 6111-6121.
22. Martinez C, Churchman M, Freeman T, Ilyas M. Osteopontin provides early proliferative drive and may be dependent upon aberrant c-myc signalling in murine intestinal tumours. Exp Mol Pathol 2010; 88: 272-277.
23. Matsuura M, Suzuki T, Saito T. Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci 2010; 101: 1828-1833.
24. Matsuura M, Suzuki T, Suzuki M, Tanaka R, Ito E, Saito T. Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep 2011; 25: 41-47.
25. Gong M, Lu Z, Fang G, Bi J, Xue X. A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett 2008; 272: 148-159.
26. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009; 17: 153-161.
27. Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol 2010; 5: 82.
28. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 2005; 26: 741-751.
29. Zhang A, Liu Y, Shen Y, Xu Y, Li X. Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells. Med Oncol 2010; 27: 1179-1184.
30. Lamour V, Le Mercier M, Lefranc F, Hagedorn M, Javerzat S, Bikfalvi A, Kiss R, Castronovo V, Bellahcène A. Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer 2010; 126: 1797-1805.